This content was archived on June 24, 2013.
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
The purpose of the following fact sheet is to provide clear and precise information to natural health product (NHP) stakeholders on Schedule A to the Food and Drugs Act (FDA) and how it pertains to NHPs. This fact sheet updates and replaces the fact sheet dated May 9, 2007.
The information found in this fact sheet has been categorized as follows:
Schedule A to the FDA is a list of diseases, disorders, or abnormal physical states. These include such things as acute anxiety, asthma, cancer and diabetes.
When the health claim (recommended use or purpose of the NHP) relates to a disease, disorder or abnormal physical state listed on Schedule A, the health claim is considered to be a “Schedule A health claim”.
Section 3(1) of the FDA prohibits the advertising to the general public of drugs, including natural health products, for the treatment, prevention or cure of the diseases, disorders, or abnormal physical states listed on Schedule A.
Further to this,
Section 3(2) of the FDA prohibits the sale of drugs, including natural health products, that are labelled, or that are advertised to the general public, for the treatment, prevention or cure of the diseases, disorders, or abnormal physical states listed on Schedule A.
On June 1, 2008, a regulatory amendment to the Natural Health Products RegulationsFootnote 1 (NHPR) came into force to remove the prohibition on the labelling and advertising of Schedule A preventative health claims.
Detailed information on the interpretation of Section 3 and its applicability to NHPs and drugs can be found in the guidance document on Schedule A and Section 3 of the Food and Drugs Act
All NHPs must undergo a pre-market review before they may be sold in Canada. This process requires that evidence supporting the safety, efficacy and quality of the product be submitted to the Natural Health Products Directorate (NHPD) for assessment by means of a product licence application. Those products supported by sufficient evidence to support the safety, efficacy and quality of the product are issued a product licence and corresponding Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM), which must appear on the product label (e.g., NPN 12345678) as proof that Health Canada has authorized the sale of the product.
The evidence required to support the safety and efficacy of an NHP making a preventative Schedule A health claim is outlined in Appendix C of the guidance document on Schedule A and Section 3 of the Food and Drugs Act.
For approved Schedule A preventative health claims:
For any other Schedule A health claim:
More information on advertising can be found in the Consumer Advertising Guidelines for Marketed Health Products (for Nonprescription Drugs including Natural Health Products)
A similar amendment was made to the Food and Drug Regulations with respect to drugs making Schedule A claims.